Follow The Filings

PHGE BiomX

BiomX earnings company data as of 7:59 PM ET 8/26

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q2 19 Aug EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by PHGE's executives, directors and 10% owners in the last 12 months, from their Form 4s

All PHGE insider trades
  • None no insider bought on the open market
  • $8.2M sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. Reuven Yeganeh Director
    Sale
    $4.9M 980,000 shares at $5.00 100% of stake
    Traded Mar 16–17 Filed Mar 18
  2. Reuven Yeganeh Director
    Sale
    $3.4M 670,000 shares at $5.00 100% of stake
    Traded Mar 12–13 Filed Mar 13

Also filed in the last 12 months, not counted as buying or selling: 4 conversions.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 3.02,9.01
8-K 3.02,8.01,9.01
DEFA14A DEFINITIVE ADDITIONAL MATERIALS
DEFA14A DEFINITIVE ADDITIONAL MATERIALS
8-K 5.02,7.01,9.01
SCHEDULE 13D/A —
DEF 14A DEFINITIVE PROXY STATEMENT
SCHEDULE 13G —
8-K 1.01,2.03,3.02,9.01
8-K 7.01,9.01
8-K 1.01,9.01
8-K 1.01,3.02,9.01
SCHEDULE 13D —
SCHEDULE 13D/A —
8-K 5.03,7.01,9.01
8-K 5.03,9.01
8-K/A 8.01,9.01
8-K 8.01,9.01
8-K 8.01,9.01
8-K 5.07,9.01
SCHEDULE 13G/A —
10-Q QUARTERLY REPORT
SCHEDULE 13G/A —
SCHEDULE 13G/A —
DEF 14A DEFINITIVE PROXY STATEMENT

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.